简介:Havingbeenpassedfor160generations,acelllinedesignatedasH22-F25/LwasestablishedfromamurinetumorlymphaticmetastatlcmodelH22-F25whichhadbeensetupinourcollege.Thecelllinewasinsuspensionculturewitharapidproliferationandstablegrowth.Thepeaktuneofcelldivisionandproliferationwas48and96hoursafterculture.Inaweek,thecellnumberwasIncreasedby25tunes.H22-F25/Lstillkeepsthefeaturesofapoorlydifferentiatedcancer.Itstumorinducingrate(invivo)was100%in615mice.Lymphnodemetastasisratewas50%andpulmonarymetastasisrate10%.H22-F25/LIsapopulationofheterogenetlctumorcellsIncluding2stemcelllines(themodelnumberofchromosomesbeing43in40%tumorcellsand86in32%)andsomesidelines.ThecommonmarkerchromosomesM1,M2,M3andM4werepresentinallstemandsidelines.
简介:近来CD4^+CD25^+调节性T细胞对肿瘤免疫调节的抑制作用正受到越来越多的重视,许多恶性肿瘤患者外周血都存在CD4^+CD25^+调节性T细胞比例上调,机体抗肿瘤免疫力下降。大肠癌的发病率正逐年上升,其发病分子机制已为熟知,免疫机制研究不多,国内尚未见大肠癌与该类细胞关系的报道,现对CD4^+CD25^+调节性T细胞在大肠癌的发生、发展、治疗中的研究综述如下。